Egetis Therapeutics
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company specializing in the late-stage development and commercialization of treatments for rare diseases within the orphan drug segment. The company focuses on addressing significant unmet medical needs. Its lead drug candidate, Emcitate, is developed for the treatment of MCT8 deficiency, a rare genetic disorder. Egetis aims to commercialize its products independently through a dedicated in-house organization, with a mission to bring unique therapies to patients that extend and improve their quality of life.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Egetis Therapeutics.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-21 07:00 |
Interim Report
|
Swedish | 3.7 MB | |
| 2025-08-21 07:00 |
Interim Report
|
English | 3.4 MB | |
| 2025-07-15 08:00 |
Regulatory News Service
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 de…
|
English | 75.2 KB | |
| 2025-07-15 08:00 |
Legal Proceedings Report
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för be…
|
Swedish | 71.1 KB | |
| 2025-05-16 00:00 |
Annual Report (ESEF)
|
Swedish | 12.4 MB | |
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Kommuniké från Egetis Therapeutics årsstämma 2025
|
Swedish | 55.3 KB | |
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
|
English | 52.3 KB | |
| 2025-04-30 07:00 |
Quarterly Report
|
Swedish | 3.7 MB | |
| 2025-04-30 07:00 |
Earnings Release
|
English | 3.3 MB | |
| 2025-02-26 07:00 |
Earnings Release
|
Swedish | 735.2 KB | |
| 2025-02-26 07:00 |
Annual Report
|
English | 764.5 KB | |
| 2025-02-13 15:25 |
Legal Proceedings Report
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and on…
|
English | 73.3 KB | |
| 2025-02-13 15:25 |
Legal Proceedings Report
EU-kommissionen godkänner Egetis Emcitate® (tiratricol) som den första och enda…
|
Swedish | 74.4 KB | |
| 2024-12-30 16:42 |
Share Issue/Capital Change
Change in the number of shares and votes in Egetis Therapeutics
|
English | 59.0 KB | |
| 2024-12-30 16:42 |
Share Issue/Capital Change
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | 65.1 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
